One-Third of Septic Shock Survivors Readmitted

This article originally appeared here.
Share this content:
One-Third of Septic Shock Survivors Readmitted
One-Third of Septic Shock Survivors Readmitted

MONDAY, July 27, 2015 (HealthDay News) -- About one-third of survivors of sepsis or septic shock are readmitted within 30 days, according to a study published online July 20 in the Journal of Hospital Medicine.

Marya D. Zilberberg, M.D., M.P.H., from the EviMed Research Group in Goshen, Mass., and colleagues examined the frequency of and risk factors for 30-day readmission among patients surviving sepsis in a single-center study. Readmission risk was examined among 1,697 survivors of hospitalization with culture-positive severe sepsis or septic shock.

The researchers found that 32.0 percent of survivors required 30-day readmission. Compared with nonreadmitted survivors, readmitted patients had a higher chronic illness burden (median Charlson score 5 versus 4; P < 0.001), but not acute illness burden (median Acute Physiology and Chronic Health Evaluation II score 15 and 15; P = 0.275); they also had higher prevalence of health care-associated sepsis (94.2 versus 90.2 percent; P = 0.014). The odds of 30-day readmission were increased with three factors: extended spectrum β-lactamase organism (odds ratio, 4.50); injury or failure on Risk Injury, Failure, Loss, End-stage criteria (odds ratio, 1.95); and Bacteroides species (odds ratio, 2.04), while two factors decreased risk: urine as source (odds ratio, 0.58) and Escherichia coli organism (odds ratio, 0.49).

"We have demonstrated that survivors of culture-positive severe sepsis or septic shock have a high rate of 30-day rehospitalization," the authors write.

The study was funded by a grant from Cubist Pharmaceuticals.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »